In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BMS Deals Diabetes Drugs, Solidifies Specialist Stance

Executive Summary

The recent diabetes alliance between Bristol-Myers Squibb and AstraZeneca on two late-stage clinical compounds highlights some of the different ways pharmaceutical companies are embracing both specialty products and externalization strategies to address the industry's growing pipeline problem. BMS and AZ are pursuing different approaches but in diabetes, those strategies are complementary: AZ's unabashed externalization and muscular primary care marketing suits BMS's gradual weaning off the blockbuster model.

Related Content

Pharmaceutical Strategic Outlook: The Trouble with Alliances
Bristol Revs Its R&D Engine: An Interview with Elliott Sigal and Francis Cuss
Deal Statistics Quarterly, Q1 2007
Can Amgen Find a New Engine?
Big Pharma Breaks the Bank in Late-Stage Licensing
Business & Technology Briefs (03/2007)
New Data Highlights Benefits, Risks of Obesity Surgery
NicOx's Naproxcinod: Hitting the NSAID Sweet Spot?
Pharmaceutical Strategic Alliances 2006: Forcing Externalization at Big Pharma
AstraZeneca Joins the In-Licensing Game


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts